Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arecor And Ligand Pharmaceuticals Sign Royalty And Technology Access Deal For AT220 And AT292 Worth Up To $11M

Author: Benzinga Newsdesk | September 25, 2025 02:54am

Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million

AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems
Arecor and Sequel Med Tech, LLC to commit up to $1.3 million each to fund development work in preparation for pivotal Phase 2 trial for AT278-Insulin Pump programme
Strategic intent is to progress to a broader co-development and commercialisation partnership for Phase 2 trial and beyond
Non-dilutive funds raised through the monetisation of Arecor's royalty rights related to AT220 and milestone and technology access fees related to AT292
Cash runway extended to 1H 2027

Posted In: LGND